Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the ...

The Phase 3 DeLLphi-304 trial data presented at ASCO 2025 showed that Imdelltra® (tarlatamab-dlle) reduced the risk of death ...

Notably, treatment usage trends from a Bladder Cancer Advocacy Network (BCAN) survey presented at GU ASCO 2025 revealed that only 1–5% of patients reported having seen a radiation oncologist and only ...

High chronic workload combined with a moderate workload ratio (1.02–1.18) had a smaller risk of injury than low chronic workload combined with several workload ratios (relative risk range from 0.3 to ...

Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

Investigators used the Shiny method, which employs artificial intelligence, to indirectly compare the efficacy of novel systemic therapies for urothelial cancer using phase 3 trial data.

Premature ASCVD in IndiaIn India, over 50% of cardiovascular disease (CVD) deaths occur before 50 years, and 25% of ...

Even higher-risk investments such as stocks have segments (such as dividend stocks) that reduce relative risk while still providing attractive long-term returns. Depending on how much risk you ...

Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali(R) (ribociclib) plus endocrine therapy (ET, a non-steroidal ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with various immunotherapies to improve outcomes in patients with non-small cell ...